SYK — Stryker Corporation

Summary of Stryker Corporation (SYK) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Organic Sales Growth: 2.4% globally, with 1.9% in the U.S. and 3.9% internationally.
• Adjusted Earnings Per Share (EPS): $2.60, down $0.24 or 8.5% from Q1 2025, primarily due to the cyber incident, tariffs, and increased interest expenses.
• Adjusted Gross Margin: 63.6%, down 190 basis points year-over-year.
• Adjusted Operating Margin: 21.1%, down 180 basis points from the previous year.
• Cash from Operations: $581 million, impacted by the cyber incident and normal seasonal outflows.

2. Strategic Updates and Business Highlights

• Cyber Incident Recovery: The company faced significant operational disruption due to a cyber incident late in Q1, but operations were fully restored by early April.
• Acquisition of Amplitude Vascular Systems: Expected to close in Q2, this acquisition aims to enhance treatment options in the peripheral vascular market.
• Formation of Ortho Tech Business: Combining Mako and Enabling Technologies with the Orthopaedic Instruments portfolio to streamline customer experience and accelerate innovation.
• Product Launches: Positive feedback on Mako Shoulder, with a full launch anticipated mid-year. The company also highlighted strong demand for Mako installations and utilization.

3. Forward Guidance and Outlook

• Full Year 2026 Guidance: Maintaining organic net sales growth expectation of 8% to 9.5% and adjusted EPS of $14.90 to $15.10. The company anticipates recovery of lost sales from Q1 throughout the remainder of the year.
• Sales Recovery: Expected to be gradual, with some recovery in Q2 and more significant improvements in Q3 and Q4 as delayed procedures and orders are fulfilled.

4. Bad News, Challenges, or Points of Concern

• Impact of Cyber Incident: The incident caused significant disruptions, affecting revenue recognition and shipment delays, particularly in capital-intensive businesses like MedSurg.
• Margin Pressure: Adjusted gross and operating margins declined due to lost manufacturing absorption and tariffs, with expectations of continued pressure from rising input costs.
• Geopolitical Risks: Ongoing conflicts, particularly in the Middle East, have had a modest impact on international growth.

5. Notable Q&A Insights

• Customer Relationships Post-Cyber Incident: Positive feedback from customers regarding Stryker's handling of the incident, with no significant loss of business reported.
• Market Dynamics: No observed slowdown in orders; hospitals are maintaining healthy balance sheets and interest in Stryker products remains strong.
• M&A Strategy: The company is open to pursuing additional acquisitions, particularly in the cardiovascular space, while maintaining a strong pipeline for future growth.
• Product Performance: Strong early feedback on Mako 4 and the Incompass Total Ankle, with expectations for significant growth once related guides receive FDA approval.

Overall, Stryker remains optimistic about its recovery trajectory and growth prospects despite facing challenges from the cyber incident and external market pressures.